New Lupus Drug Drug to Generate $2 Billion in Annual Sales for GSK and HGSI

Every so often, a new approval generates Significant Attention. And the endorsement of FDA Benlysta, The First New Treatment for lupus in 56 years, is one of Those Moments. The Injectable med, Which Will Be marketed by Human Genome Sciences (HGSI) and GlaxoSmithKline (GSK), is forecast Thurs Generate at Least $ 2 Billion in annual sales thanks to a $ 35.000 price tag, despite Cautionary language for Certain Patients ".

The med, Which Will Actually cost about $ 40,000 in the first year, Will Become available later this month. There is no REMS Requirement or Black Box warning, Which heartened Wall Street. Nonetheless, insurance reimbursement Remains Somewhat fuzzy. Meanwhile, Human Genome Sciences Agreed Thurs Conduct Another clinical trial in African-American Lupus Patients ". Here's why ...read more at http://seekingalpha.com